Awake Transnasal Laser-assisted Surgery (TNLS) and Microlaryngeal Surgery for Vocal Cord Cyst
Launched by CHINESE UNIVERSITY OF HONG KONG · Nov 20, 2024
Trial Information
Current as of November 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to treat vocal cord cysts, which are growths on the vocal cords that can affect your voice. The trial is comparing a newer method called awake transnasal laser-assisted laryngeal surgery (TNLS), which is done in the office with local anesthesia (numbing medicine), to the traditional method known as microlaryngeal surgery, which is performed in a hospital under general anesthesia (where you are fully asleep). Researchers want to find out which method works better in terms of success and recovery for patients.
To participate in this trial, you need to be at least 18 years old, have a vocal cord cyst, and be able to give consent on your own. You also need to be able to handle a procedure called flexible laryngoscopy, which allows doctors to see your vocal cords. However, if you're under 18, cannot provide consent, have certain allergies, or have other specific medical conditions, you won't be eligible. If you decide to take part, you can expect to receive one of the two treatments and help researchers understand which option is better for treating vocal cord cysts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with vocal cord cysts
- • older than 18-year-old
- • able to independently provide consent
- • able to tolerate flexible laryngoscopy would be recruited
- Exclusion Criteria:
- • under 18-year-old
- • unable to independently give an informed consent
- • unable to tolerate flexible laryngoscopy
- • allergic to local anesthesia
- • had unfavorable anatomy such as prolapsing epiglottis precluding adequate visualization, extensive lesions and an expected difficult operation as judged by the surgeons
- • with pathologies other than vocal cord cyst
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported